Raymond James Financial Inc. bought a new stake in shares of HF Sinclair Co. (NYSE:DINO – Free Report) during the fourth ...

Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th ...

Victory Capital Management Inc. decreased its stake in HF Sinclair Co. (NYSE:DINO – Free Report) by 51.8% in the fourth ...

Learn more about whether HF Sinclair Corporation or Sunoco LP is a better investment based on AAII's A+ Investor grades, ...

Net Revenue Increased 8.7% and 4.6% for the Fourth Quarter and Full Year 2024, RespectivelyPre-Recorded Earnings Call Webcast Available on ...

The FDA has accepted for Priority Review the sNDA for finerenone for heart failure with mildly reduced or preserved ejection fraction.

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

Senate lawmakers amended the bill passed by the Iowa House last week, which means it will be sent back to House lawmakers for another vote.

The PREDICT-HFpEF tool predicts cardiovascular risk, and finerenone remains effective for heart failure across baseline risk levels.

The company reported adjusted earnings per share of $0.11 for the fourth quarter, exceeding the analyst consensus estimate of $0.09. Revenue for the quarter was $305.3 million, topping the consensus ...

Gross profit margin decreased to 17.1% from 18.6% in the prior year period ... we made significant strides in executing our operational transformation plan, positioning HF Foods to capitalize on the ...